UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Wed Dec 24, 11:19AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
INTG: 17.90 (+0.01), NICK: 14.80 (+0.20), ADXS: 7.57 (+0.50), WBKC: 23.47 (+0.03), SOCB: 7.20 (+0.03), CBIN: 27.50 (-0.28), UPI: 2.30 (unch), CTIB: 3.74 (-0.06), SONA: 11.29 (unch)
UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Vision-Sciences, Inc.
Business Wire - Tue Dec 23, 10:40AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Uroplasty, Inc. ("Uroplasty"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. -- UPI
PR Newswire - Tue Dec 23, 10:22AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
UROPLASTY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Dec 22, 11:42AM CST
Rigrodsky & Long, P.A.:
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Mon Dec 22, 9:42AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
Uroplasty and Vision-Sciences to Merge, Creating Innovative Medical Device Company Positioned for Growth
GlobeNewswire - Mon Dec 22, 6:00AM CST
All-Stock Combination Creates New Company with Expanded Product Offerings in Urology
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth
PR Newswire - Mon Dec 22, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) entered into a definitive merger agreement under which the two companies will combine in an all-stock transaction to create a new company expected to generate revenue of approximately $50 million for the fiscal year beginning April 1, 2015.
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
Uroplasty To Participate In The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum
PR Newswire - Thu Nov 13, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum on Thursday, November 20.
UPI: 2.30 (unch)
Uroplasty FQ2 revenues up 12%
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 8:04AM CDT
UPI: 2.30 (unch)
Uroplasty's (UPI) CEO Robert Kill on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 7:06PM CDT
UPI: 2.30 (unch)
Uroplasty beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 3:46PM CDT
UPI: 2.30 (unch)
Uroplasty Reports Record Fiscal Second Quarter Revenue
PR Newswire - Thu Oct 23, 3:01PM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 second quarter ended September 30, 2014.
UPI: 2.30 (unch)
Healthcare Industry Leader Kenneth H. Paulus Joins Uroplasty's Board of Directors
PR Newswire - Wed Oct 15, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that Kenneth H. Paulus has been appointed to the Company's Board of Directors effective October 15, 2014. Mr. Paulus will chair the Board's compensation committee and serve on the nominating committee.
UPI: 2.30 (unch)
Uroplasty to Announce Second Quarter Fiscal Year 2015 Financial Results on October 23, 2014
PR Newswire - Thu Oct 09, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, will release financial results for the second quarter ended September 30, 2014 after the market close on Thursday, October 23, 2014.
UPI: 2.30 (unch)
Uroplasty To Participate In The 5th Annual Craig-Hallum Alpha Select Conference
PR Newswire - Wed Sep 10, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 5th Annual Craig-Hallum Alpha Select Conference on Thursday, September 18.
UPI: 2.30 (unch)
Electromed, Inc. Names Lee Jones to its Board of Directors
Business Wire - Tue Sep 02, 3:30PM CDT
Electromed, Inc. (NASDAQ: ELMD), announced today that its Board of Directors has elected Lee Jones to the Board. Ms. Jones has served as the President and Chief Executive Officer of Rebiotix Inc. since 2011 and as a director of Uroplasty, Inc. since 2006.
UPI: 2.30 (unch), ELMD: 2.54 (+0.01)
Uroplasty To Participate In Canaccord Genuity 34th Annual Growth Conference
PR Newswire - Wed Aug 06, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13.
UPI: 2.30 (unch)
Uroplasty Reports Fiscal First Quarter Results
PR Newswire - Thu Jul 24, 3:01PM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 first quarter ended June 30, 2014.
UPI: 2.30 (unch)
Uroplasty To Announce First Quarter Fiscal Year 2015 Financial Results On July 24, 2014
PR Newswire - Thu Jul 10, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, will release financial results for the first quarter ended June 30, 2014 after the market close on Thursday, July 24, 2014.
UPI: 2.30 (unch)